Eli Lilly touts PhIII mirikizumab win in Crohn’s despite woes in other conditions

Lei Lei Wu

News Reporter

Eli Lilly said its anti-inflammatory medicine mirikizumab helped about half of people with Crohn’s disease enter remission after one year in a Phase III study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly touts PhIII mirikizumab win in Crohn’s despite woes in other conditions

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Eli Lil­ly touts PhI­II mirik­izum­ab win in Crohn’s de­spite woes in oth­er con­di­tions

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Eli Lilly touts PhIII mirikizumab win in Crohn’s despite woes in other conditions